Otsuka Holdings Co., Ltd. (OTSKF)
| Previous close | 40.88 |
| Open | 39.48 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 39.48 - 39.48 |
| 52-week range | 35.91 - 41.59 |
| Volume | |
| Avg. volume | 79 |
| Market cap | 22.377B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 24.52 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (2.02%) |
| Ex-dividend date | 27 June 2024 |
| 1y target est | N/A |
- Zacks
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
- Reuters
US FDA approves Otsuka's blood pressure treatment device for use
The U.S. Food and Drug Administration (FDA) approved the use of a device made by an Otsuka Holdings unit in a type of surgery to treat high blood pressure, the company said on Wednesday. The approval for Paradise Ultrasound Renal Denervation comes after an FDA panel backed its use. The device is made by Japanese company Otsuka's unit ReCor and is indicated for use in patients whose hypertension, or high blood pressure, cannot be controlled with drugs.
- Motley Fool
This Big Pharma Company Is Becoming a Psychedelics Stock, but Don't Buy It (Yet)
As the first large pharma operation to make a significant investment in psychedelics, the rewards could be big.
